A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Рандомизированное исследование интенсивного и стандартного контроля артериального давления
2015-11-09
SCID: 54.1/25abrkux
Discuss with AI
All-cause mortalityCardiovascular eventsIntensive blood-pressure controlSPRINT trialSystolic blood-pressure target
Figures from the paper
Abstract (AI)
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Key Findings
1
After 1 year, mean systolic blood pressure was 121.4 mm Hg with intensive treatment and 136.2 mm Hg with standard treatment.
2
All-cause mortality was lower with intensive treatment (hazard ratio, 0.73; P=0.003).
3
In adults with elevated systolic blood pressure, increased cardiovascular risk, and no diabetes, intensive treatment targeted below 120 mm Hg versus below 140 mm Hg.
4
Intensive treatment increased serious adverse events involving hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not injurious falls.
5
Intensive treatment reduced the primary composite cardiovascular outcome from 2.19% to 1.65% per year (hazard ratio, 0.75; P<0.001).
Research Object
Adults without diabetes with systolic blood pressure of 130 mm Hg or higher and increased cardiovascular risk
Research Subject
Effects and safety of intensive versus standard systolic blood-pressure targets on major cardiovascular events, mortality, and adverse events
Publication Details
Publication Date
2015-11-09
Journal
Publisher
ISSN
Cited by
6539
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by20
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2021
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2016
2018 ESC/ESH Guidelines for the management of arterial hypertension2018
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association2023
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2017
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 20152016
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2016
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)2017
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association2024
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20162017
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure2022
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension2021
Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association2019
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
Clinical Update: Cardiovascular Disease in Diabetes Mellitus2016
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions2021